4-(4-fluorobenzylidene)piperidine hydrochloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(4-fluorobenzylidene)piperidine hydrochloride
• 英文别名: 4-(4-fluorobenzylidene)-piperidine hydrochloride；4-[(4-fluorophenyl)methylidene]piperidine;hydrochloride
• 化学式: C₁₂H₁₄FN*ClH
• 分子量: 227.709
• InChiKey: ALVRAPXLHVZNHU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.01
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  12
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(4-fluorobenzylidene)piperidine hydrochloride 、 2-哌啶羧酸,1-乙基-,(2S)- 生成 ((2S)-1-Ethylpiperidin-2-yl)-[4-(4-fluoro Benzylidene)piperidin-1-yl]methanone Hydrochloride
  参考文献：
  名称：

  Modulators of the cholesterol biosynthetic pathway

  摘要：

  本发明涉及调节胆固醇生物合成途径的方法。体内胆固醇水平与许多病理状态相关。本发明的方法改变了参与胆固醇生物合成的基因的转录水平。本发明的方法可用于治疗由胆固醇生物合成途径介导的疾病。

  公开号：

  US20030191110A1
• 作为产物：
  描述：

  tert-butyl 4-(4-fluorobenzylidene)piperidine-1-carboxylate 以 乙酸乙酯 为溶剂， 以96%的产率得到4-(4-fluorobenzylidene)piperidine hydrochloride
  参考文献：
  名称：

  Modulators of the cholesterol biosynthetic pathway

  摘要：

  本发明涉及调节胆固醇生物合成途径的方法。体内胆固醇水平与许多病理状态相关。本发明的方法改变了参与胆固醇生物合成的基因的转录水平。本发明的方法可用于治疗由胆固醇生物合成途径介导的疾病。

  公开号：

  US20030191110A1

文献信息

• Heteroaromatic derivatives
  申请人：Taisho Pharmaceutical Co., Ltd.

  公开号：US06291467B1

  公开（公告）日：2001-09-18

  An aromaheterocyclic derivative represented by the formula: wherein Z is a group represented by the following formula: wherein Ar1 is a phenyl group or a phenyl group substituted with a halogen atom or an alkyl group of 1 to 5 carbon atoms, R2 is an alkyl group of 1 to 5 carbon atoms, Y is a hydrogen atom, a mercapto group, an alkylthio group of 1 to 5 carbon atoms, an amino group or an amino group substituted with one or two alkyl groups having 1 to 5 carbon atoms, Ar2 is a phenyl group of one or two substituents selected from the group consisting of a halogen atom, an alkyl group of 1 to 5 carbon atoms, an alkoxy group of 1 to 5 carbon atoms, a hydroxyl group and a trifluoromethyl group, or a phenyl group, B1-B2 is CH—CO or C═C(R1) (wherein R1 is a hydrogen atom or an alkyl group of 1 to 5 carbon atoms), and n is an integer of 1 to 4, or a pharmaceutically acceptable salt thereof, which is a dopamine D4 receptor antagonist compound having an antipsychotic action without causing extrapyramidal diseases.

  一种芳香杂环衍生物，其结构式如下：其中Z为以下结构式所示的基团：其中Ar1为苯基或被卤素原子或1至5个碳原子的烷基取代的苯基，R2为1至5个碳原子的烷基，Y为氢原子、巯基、1至5个碳原子的烷硫基、氨基或被一个或两个1至5个碳原子的烷基取代的氨基，Ar2为具有一个或两个选自卤素原子、1至5个碳原子的烷基、1至5个碳原子的烷氧基、羟基和三氟甲基的取代基的苯基，或苯基，B1-B2为CH—CO或C═C(R1)（其中R1为氢原子或1至5个碳原子的烷基），n为1至4的整数，或其药学上可接受的盐，该化合物是一种具有抗精神病作用而不引起锥体外系疾病的D4多巴胺受体拮抗剂。
• THIAZOLE DERIVATIVES
  申请人：TAISHO PHARMACEUTICAL CO. LTD

  公开号：EP0816362A1

  公开（公告）日：1998-01-07

  The present invention relates to a thiazole derivative represented by formula (I) wherein Ar1 represents a substituted or unsubstituted phenyl or thienyl group, Y1 and Y2 are different and each represents a nitrogen atom or a sulfur atom, R1 represents a hydrogen atom, a C1 to C5 alkyl group, a phenyl group, or an amino group unsubstituted or mono- or di-substituted with a C1 to C5 alkyl group, and R2 represents a substituted or unsubstituted nitrogen heterocycle group, or a pharmaceutically acceptable salt thereof. The compound of the present invention are a dopamine D4 receptor antagonist which has an antipsychotic effect without causing any extrapyramidal disorder.

  本发明涉及一种由式(I)表示的噻唑衍生物，其中Ar1代表一个取代或未取代的苯基或噻吩基团，Y1和Y2不同，每个代表一个氮原子或硫原子，R1代表一个氢原子，一个C1到C5烷基基团，一个苯基，或一个未取代或单取代或双取代的氨基基团，其取代基为C1到C5烷基基团，R2代表一个取代或未取代的氮杂环基团，或其药用可接受的盐。本发明的化合物是多巴胺D4受体拮抗剂，具有抗精神病作用，而不会导致任何锥体外症状障碍。
• [EN] NEW HETEROCYCLIC CARBOXYLIC ACID AMIDE DERIVATIVES<br/>[FR] NOUVEAUX DERIVES AMIDES D'ACIDE CARBOXYLIQUE HETEROCYCLIQUE
  申请人：RICHTER GEDEON VEGYESZET

  公开号：WO2006010969A1

  公开（公告）日：2006-02-02

  The invention relates to new heterocyclic carboxylic acid amide derivatives of formula (I) - wherein the meaning of X is hydrogen or halogen atom, hydroxy, cyano, C1-C4 alkylsulfonamido optionally substituted by a halogen atom or halogen atoms, C1-C4 alkanoylamido optionally substituted by a halogen atom or halogen atoms, arylsulfonamido groups, is -CH= group or -N= atom, Z is one or more hydrogen or halogen atom, C1-C4 alkyl, C1-C4 alkoxy, cyano, trifluoromethyl, trifluoromethoxy group and to the salts thereof, which are antagonists of NMDA receptor or are intermediates for preparing thereof.

  该发明涉及公式（I）的新杂环羧酸酰胺衍生物，其中X的含义是氢或卤素原子，羟基，氰基，C1-C4烷基磺酰胺（可选择地由卤素原子或卤素原子取代），C1-C4烷酰胺（可选择地由卤素原子或卤素原子取代），芳基磺酰胺基团，-CH=基团或-N=原子，Z是一个或多个氢或卤素原子，C1-C4烷基，C1-C4烷氧基，氰基，三氟甲基，三氟甲氧基团及其盐，这些衍生物是NMDA受体的拮抗剂或用于其制备的中间体。
• 2-carbonylthiazole derivatives and use of the same
  申请人：Taisho Pharmaceutical Co., Ltd.

  公开号：US06166033A1

  公开（公告）日：2000-12-26

  This invention provides a 2-carbonylthiazole derivative represented by formula (I): ##STR1## wherein each of Ar.sup.1 and Ar.sup.2 represents a phenyl group or a substituted phenyl group; R.sup.1 represents an alkoxy group having 1 to 5 carbon atoms, a hydroxyl group or an amino group; Y.sup.1 --Y.sup.2 represents CH--CO or C.dbd.CR.sup.2, wherein R.sup.2 represents a hydrogen atom or an alkyl group having 1 to 5 carbon atoms; and n is an integer of from 1 to 4, or a pharmaceutically acceptable salt thereof. The disclosed compounds are useful as drugs for preventing and treating dopamine D receptor-related morbid states such as schizophrenia and problematic behavior caused by cerebrovascular accidents and senile dementia and do not induce extrapyramidal disorders as side effects.

  本发明提供了由公式(I)表示的2-羰基噻唑衍生物：##STR1## 其中Ar.sup.1和Ar.sup.2分别表示苯基或取代苯基；R.sup.1表示具有1到5个碳原子的烷氧基，羟基或氨基；Y.sup.1--Y.sup.2表示CH--CO或C.dbd.CR.sup.2，其中R.sup.2表示氢原子或具有1到5个碳原子的烷基；n为1到4的整数，或其药学上可接受的盐。所述化合物可用作预防和治疗多巴胺D受体相关的病态状态，如精神分裂症和脑血管意外和老年性痴呆引起的问题行为的药物，并不会引起锥体外系障碍作为副作用。
• Heterocyclic Carboxylic Acide Amide Derivatives
  申请人：Borza Istvan

  公开号：US20080300276A1

  公开（公告）日：2008-12-04

  The invention relates to new heterocyclic carboxylic acid amide derivatives of formula (I)—wherein the meaning of X is hydrogen or halogen atom, hydroxy, cyano, C 1 -C 4 alkylsulfonamido optionally substituted by a halogen atom or halogen atoms, C 1 -C 4 alkanoylamido optionally substituted by a halogen atom or halogen atoms, arylsulfonamido groups, is —CH═ group or —N═ atom, Z is one or more hydrogen or halogen atom, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, cyano, trifluromethyl, trifluoromethoxy group and to the salts thereof, which are antagonists of NMDA receptor or are intermediates for preparing thereof.

  本发明涉及一种新的杂环羧酸酰胺衍生物，其化学式为（I），其中X的含义为氢原子或卤素原子、羟基、氰基、C1-C4烷基磺酰胺基（可选地被卤素原子或卤素原子取代）、C1-C4酰胺基（可选地被卤素原子或卤素原子取代）、芳基磺酰胺基、-CH═基或-N═原子，Z为一个或多个氢原子或卤素原子、C1-C4烷基、C1-C4烷氧基、氰基、三氟甲基、三氟甲氧基，以及其盐，它们是NMDA受体拮抗剂或其制备的中间体。